Risks of suboptimal and excessive thyroid hormone replacement across ages
Research output: Contribution to journal › Review › Research › peer-review
Documents
- Fulltext
Final published version, 484 KB, PDF document
Background: Hypothyroidism is prevalent at all ages and represents a non-communicable disease with preventable consequences. Method: Narrative review. Review: In children and adolescents, the most devastating consequences of undertreatment with levothyroxine (LT4) are poor growth and development. Delayed treatment in congenital hypothyroidism can lead to permanent brain damage. In young to middle-aged adults, symptoms are often overlooked, and treatment delayed by many years. The resulting consequences are also at this age group compromised brain and physical function but less severe and partly reversible with treatment. The under-treated condition often results in a higher risk of, e.g., increased cardiovascular disease burden, obesity, hypertension, poor physical capacity, and poor quality of life. Excessive replacement is at all adult age groups associated with increased risk of cardiac death, osteoporosis, loss of muscle function, psychological instability and poor quality of life. In young fertile women, the consequences of undertreatment with LT4 are subnormal fertility, recurrent pregnancy loss, compromised fetal growth, and neurocognitive development. On the other hand, excessive LT4 treatment has been related to gestational hypertension, preeclampsia and preterm birth. In the elderly, care must be given to avoid confusing a slightly high age-related serum TSH with requirement for LT4 treatment in a truly hypothyroid patient. Excessive LT4 treatment in patients of high age is associated with an increased mortality. Conclusion: Suboptimal and excessive LT4 replacement of the preventable non-communicable disease hypothyroidism requires more focus from the healthcare system and from the global political systems to prevent the personally devastating and socioeconomically challenging consequences.
Original language | English |
---|---|
Journal | Journal of Endocrinological Investigation |
Volume | 47 |
Issue number | 5 |
Pages (from-to) | 1083-1090 |
ISSN | 0391-4097 |
DOIs | |
Publication status | Published - 2024 |
Bibliographical note
Funding Information:
This is study was funded by Kirsten og Freddy Johansens Fond, Novo Nordisk Fonden, ID 0077221, Sofie Bliddal.
Funding Information:
UFR’s research salary was sponsored by The Kirsten and Freddy Johansen’s Fund. SB’s research salary was sponsored by a grant from the Novo Nordisk Foundation (ID 0077221).
Publisher Copyright:
© 2023, The Author(s).
- Hypothyroidism, Non-communicable disease, Replacement, Suboptimal treatment
Research areas
ID: 387977789